413 related articles for article (PubMed ID: 11118066)
41. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.
Nicholson JK; Browning SW; Hengel RL; Lew E; Gallagher LE; Rimland D; McDougal JS
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):105-15. PubMed ID: 11404531
[TBL] [Abstract][Full Text] [Related]
42. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
43. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
[TBL] [Abstract][Full Text] [Related]
44. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
45. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
[TBL] [Abstract][Full Text] [Related]
46. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
[TBL] [Abstract][Full Text] [Related]
47. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
48. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
[TBL] [Abstract][Full Text] [Related]
49. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection.
Hejdeman B; Lenkei R; Leandersson AC; Hultström AL; Wahren B; Sandström E; Bratt G
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):277-86. PubMed ID: 11242515
[TBL] [Abstract][Full Text] [Related]
50. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART.
Romiti ML; Cancrini C; Castelli-Gattinara G; Di Cesare S; Ciaffi P; Bernardi S; De Gasperi MR; Halapi E; Rossi P
AIDS; 2001 Nov; 15(16):2075-84. PubMed ID: 11684926
[TBL] [Abstract][Full Text] [Related]
51. Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
Di Mascio M; Sereti I; Matthews LT; Natarajan V; Adelsberger J; Lempicki R; Yoder C; Jones E; Chow C; Metcalf JA; Sidorov IA; Dimitrov DS; Polis MA; Kovacs JA
J Virol; 2006 Mar; 80(6):2665-74. PubMed ID: 16501076
[TBL] [Abstract][Full Text] [Related]
52. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
Ortiz GM; Wellons M; Brancato J; Vo HT; Zinn RL; Clarkson DE; Van Loon K; Bonhoeffer S; Miralles GD; Montefiori D; Bartlett JA; Nixon DF
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13288-93. PubMed ID: 11687611
[TBL] [Abstract][Full Text] [Related]
53. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
[TBL] [Abstract][Full Text] [Related]
54. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.
Li TS; Tubiana R; Katlama C; Calvez V; Ait Mohand H; Autran B
Lancet; 1998 Jun; 351(9117):1682-6. PubMed ID: 9734884
[TBL] [Abstract][Full Text] [Related]
55. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART.
Baldanti F; Paolucci S; Gulminetti R; Maserati R; Migliorino G; Pan A; Maggiolo F; Comolli G; Chiesa A; Gerna G
Antiviral Res; 2001 Jun; 50(3):197-206. PubMed ID: 11397507
[TBL] [Abstract][Full Text] [Related]
56. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
Hazenberg MD; Stuart JW; Otto SA; Borleffs JC; Boucher CA; de Boer RJ; Miedema F; Hamann D
Blood; 2000 Jan; 95(1):249-55. PubMed ID: 10607709
[TBL] [Abstract][Full Text] [Related]
57. [Complete immune and clinical recovery after highly active antiretroviral therapy in advanced vertically HIV-1 infected children].
Resino S; Sánchez-Ramón S; Correa R; Navarro ML; Bellón JM; Muñoz-Fernández MA
Med Clin (Barc); 2003 Mar; 120(11):417-20. PubMed ID: 12681220
[TBL] [Abstract][Full Text] [Related]
58. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients.
Libois A; López A; Garcia F; Castro P; Maleno MJ; García A; Climent N; Arnedo M; Gallart T; Gatell JM; Plana M
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):657-66. PubMed ID: 16831090
[TBL] [Abstract][Full Text] [Related]
59. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy.
Sadeghi M; Süsal C; Daniel V; Naujokat C; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):886-90. PubMed ID: 17678471
[TBL] [Abstract][Full Text] [Related]
60. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
Powles T; Imami N; Nelson M; Gazzard BG; Bower M
AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
